| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1996;111:935-940
© 1996 Mosby, Inc.
GENERAL THORACIC SURGERY |
From the Departments of Thoracic and Cardiovascular Surgery, Hematology and Medical Oncology, Biostatistics and Epidemiology, Gastroenterology, and Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio.
Received for publication June 21, 1995 Revisions requested Oct. 2, 1995; revisions received Oct. 20, 1995 Accepted for publication Dec. 21, 1995. Address for reprints: Thomas W. Rice, MD, The Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195.
Abstract
Objective: Stage II esophageal carcinomas are a heterogeneous group of uncommon malignant tumors that include both node-negative (IIA; T2 N0 M0 and T3 N0 M0) and node-positive (IIB; T1 N1 M0 and T2 N1 M0) carcinomas. The purpose of this study was to evaluate this heterogeneity and to identify predictors of improved survival. Results: Ninety-four of 345 patients undergoing esophageal resection at the Cleveland Clinic Foundation between 1985 and 1994 had stage II carcinomas; 70 stage IIA (24 T2 N0 M0 and 46 T3 N0 M0) and 24 stage IIB (9 T1 N1 M0 and 15 T2 N1 M0). Pathologic stage and T and N status were the only identifiable predictors of survival. Stage IIA survival was significantly better than stage IIB (p = 0.01). T2 N0 M0 survival was not different from T1 N0 M0 survival (p = 0.83). T3 N0 M0 survival was significantly worse than T1 N0 M0 (p = 0.03) and intermediate between T2 N0 M0 survival (p = 0.06) and T1 N1 M0 and T2 N1 M0 survivals (p = 0.07). T1 N1 M0 and T2 N1 M0 survival was not significantly different from T3 N1 M0 survival (p = 0.63). Conclusions: (1) N1 disease is the principal predictor of reduced survival and N1 is independent of T. Therefore the distinction between T1 N1 M0, T2 N1 M0, and T3 N1 M0 carcinomas is not warranted. (2) N0 disease is the principal predictor of improved survival but N0 is not independent of T. T1 N0 M0 and T2 N0 M0 survivals are similar and therefore distinction between these subgroups is not warranted. T3 N0 M0 survival is intermediate between T1 N0 M0 and T2 N0 M0 carcinomas and between T1 N1 M0, T2 N1 M0, and T3 N1 M0 carcinomas. Therefore stratification by T for N0 carcinomas is warranted. (J THORACCARDIOVASCSURG1996;111:935-40)
This article has been cited by other articles:
|
|
 |
|
  R. J. Cerfolio, A. S. Bryant, A. A. Talati, R. M. Cerfolio, and T. S. Winokur Change in maximum standardized uptake value on repeat positron emission tomography after chemoradiotherapy in patients with esophageal cancer identifies complete responders. J. Thorac. Cardiovasc. Surg., March 1, 2009; 137(3): 605 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Kim, K. H. Lee, Y. H. Kim, S. W. Sung, S. Jheon, S.-k. Cho, and K. W. Lee Postoperative Imaging of Esophageal Cancer: What Chest Radiologists Need to Know RadioGraphics, March 1, 2007; 27(2): 409 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Lagarde, F. J.W. ten Kate, J. B. Reitsma, O. R.C. Busch, and J. J. B. van Lanschot Prognostic Factors in Adenocarcinoma of the Esophagus or Gastroesophageal Junction J. Clin. Oncol., September 10, 2006; 24(26): 4347 - 4355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hagen and T. R. DeMeester Staging of esophageal carcinoma J. Thorac. Cardiovasc. Surg., May 1, 2003; 125(5): 988 - 991. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W.C. Entwistle III and M. Goldberg Multimodality therapy for resectable cancer of the thoracic esophagus Ann. Thorac. Surg., March 1, 2002; 73(3): 1009 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Rice, E. H. Blackstone, J. R. Goldblum, M. M. DeCamp, S. C. Murthy, G. W. Falk, A. H. Ormsby, L. A. Rybicki, J. E. Richter, and D. J. Adelstein Superficial adenocarcinoma of the esophagus J. Thorac. Cardiovasc. Surg., December 1, 2001; 122(6): 1077 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-P. Hsu, C.-Y. Chen, J.-Y. Hsia, and S.-E. Shai Prediction of prognosis by the extent of lymph node involvement in squamous cell carcinoma of the thoracic esophagus Eur. J. Cardiothorac. Surg., January 1, 2001; 19(1): 10 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Chidel, T. W. Rice, D. J. Adelstein, P. A. Kupelian, J. H. Suh, and M. Becker Resectable Esophageal Carcinoma: Local Control with Neoadjuvant Chemotherapy and Radiation Therapy Radiology, October 1, 1999; 213(1): 67 - 72. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. E. Reed Surgical Management of Esophageal Carcinoma Oncologist, April 1, 1999; 4(2): 95 - 105. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Tachibana, S. Kinugasa, D. K. Dhar, H. Tabara, R. Masunaga, T. Kotoh, H. Kubota, and N. Nagasue Prognostic Factors in T1 and T2 Squamous Cell Carcinoma of the Thoracic Esophagus Arch Surg, January 1, 1999; 134(1): 50 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Mansour, V. H. Thourani, and W. A. Cooper Esophageal Carcinoma: Surgery Without Preoperative Adjuvant Chemotherapy Ann. Thorac. Surg., May 1, 1998; 65(5): 1492 - 1493. [Full Text] [PDF]
|
|
|
|
|
|
R. J. Korst, V. W. Rusch, E. Venkatraman, M. S. Bains, M. E. Burt, R. J. Downey, and R. J. Ginsberg Proposed Revision Of The Staging Classification For Esophageal Cancer J. Thorac. Cardiovasc. Surg., March 1, 1998; 115(3): 660 - 670. [Abstract] [Full Text]
|
|
|
|
|
|
N. K. Altorki, L. Girardi, and D. B. Skinner EN BLOC ESOPHAGECTOMY IMPROVES SURVIVAL FOR STAGE III ESOPHAGEAL CANCER J. Thorac. Cardiovasc. Surg., December 1, 1997; 114(6): 948 - 956. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
